Tagged with

Ukraine Ukraine’s bold decision to outsource public procurement of medicines to international agencies to combat rampant corruption has been well received by the pharma MNCs operational in the country, but faces criticism from domestic players. “Healthcare procurement was widely considered as one of the areas most seriously altered by corruption” Tetiana…

Generics With cost-cutting measures exacerbating an already fraught regulatory process, the Canadian generics industry is facing somewhat of an existential crisis. However, within this difficult market environment, enterprising generics companies are still seeing significant opportunities for growth. “Sometimes it seems as if [non-industry members] believe generic products grow on trees” Jim…

Brazil Nelson Mussolini, executive president of the syndicate of the pharmaceutical industry in the State of Sao Paulo (Sindusfarma), which represents around 95 percent of all pharmaceutical marketing in the country and gathers together over 312 associate members overall, documents the exceptional growth of the pharmaceutical industry in Brazil despite the…

Bulgaria Vladimir Afenliev, chief director business operations, strategic and organizational developments at Sopharma, explains the great success of the strongest Bulgarian pharmaceutical company in the country as well as the upcoming strategies to further grow Sopharma in the region. Sopharma is the most important pharmaceutical group in Bulgaria with activities spanning…

Bulgaria Yavor Kostov, country manager at Mylan in Bulgaria, discloses his strategies to successfully lead an affiliate through corporate changes and explains the important mission of Mylan to provide high-quality treatments to people around the world in general and Bulgaria in particular.  As you are a medical doctor by training, what…

Tunisia Alya El Hedda, GM of Opalia-Recordati in Tunisia, describes the Opalia affiliate’s evolution since the Recordati takeover, her ambitions for the future, and how the company will leverage its production facilities – the largest in Tunisia – to become Recordati’s export hub for the rest of Africa and MENA. Could…

Tunisia Slim Chouchane, general director of Alfasigma in Tunisia, discusses the integration with Sigma Tau, the Italian company acquired by Alfa Wassermann in 2016, Chouchane retraces the incredible success of Alfa Wassermann’s products over his 17 years with the company and his responsibility for the company’s sound growth in the region.…

Brazil Antonio Britto, the executive president of Interfarma, the main association gathering together local and international innovators in Brazil, provides insights into some of the hottest topics in Brazil’s pharmaceutical sector, including an assessment of the eye-catching growth prospects of the industry after years of political and economy turmoil, as well…

Canada Chirfi Guindo, president and managing director of Merck Canada, highlights the stunning transformation that has led to a revitalized new Merck affiliate, the innovation opportunities Canada’s fragmented and diverse health systems offers, and the importance of greater collaboration and dialogue between all stakeholders within Canada’s healthcare and innovation ecosystem. Three…

Tunisia Chokri Jeribi, country chair of Sanofi Tunisia since 2016, is responsible for the development and market leadership hold of Sanofi’s affiliate in Tunisia. In this interview he stresses the importance that clinical trials activities for both the company and the country. Additionally, Jeribi documents the unique collaboration system with local…

Brazil Eduardo Martins, president director of Pharlab, provides insights into the “2020 vision” that has been driving the eye-catching development of this ambitious domestic company and documents how Pharlab is leveraging the expertise and added value brought by France’s Biogaran, the company’s new owners, to sharpen its competitive advantage in the…

Austria Gerhard Hirczi of the Vienna Business Agency and Peter Halwachs of LISAvienna describe Vienna’s impressive footprint in the life sciences, its positioning as the start-up hub for Central and Eastern Europe, and the potential ramifications of the European Medicines Agency (EMA) relocating to the city. Could you please start by…